Physician profile
Heidi M Hoffman
NPI 1205826328
$1,612.04
in general payments reported to CMS, 2019-2025
20 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2022: $400 · 2023: $222 · 2024: $335 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $336.77 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $276.27 | 2021-2025 | Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $196.21 | 2021-2025 | Injectafer |
| Abbvie INC. | $191.36 | 2022-2024 | |
| Amgen INC. | $114.71 | 2023-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $80.60 | 2021-2025 | |
| Exact Sciences Corporation | $59.24 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Heartflow, INC. | $54.53 | 2023-2024 | Ffrct |
| Glaxosmithkline, LLC. | $39.75 | 2021-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $36.84 | 2022-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $35.87 | 2024 | Voquezna |
| Inari Medical, INC. | $34.88 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $33.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.58 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.64 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17.59 | 2023 | Proclaim |
| E.R. Squibb & Sons, L.L.C. | $16.66 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.53 | 2021 | |
| Cipher Pharmaceuticals US LLC | $15.51 | 2025 | Natroba, Spinosad |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.34 | 2024 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.